David M Holtzman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4023708/publications.pdf

Version: 2024-02-01

465 papers	97,889 citations	179 152 h-index	278 295 g-index
529 all docs	529 docs citations	529 times ranked	57748 citing authors

#	Article	IF	Citations
1	The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 270-279.	0.4	7,498
2	NIAâ€AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 535-562.	0.4	5,861
3	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. New England Journal of Medicine, 2012, 367, 795-804.	13.9	3,005
4	The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity, 2017, 47, 566-581.e9.	6.6	1,741
5	Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell, 2019, 179, 312-339.	13.5	1,675
6	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 2016, 12, 292-323.	0.4	1,318
7	The Role of Apolipoprotein E in Alzheimer's Disease. Neuron, 2009, 63, 287-303.	3.8	1,251
8	TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimerâ€™s Disease Model. Cell, 2015, 160, 1061-1071.	13.5	1,236
9	Amyloid-Î² Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle. Science, 2009, 326, 1005-1007.	6.0	1,222
10	Clearance of Alzheimerâ€™s amyloid-Î²1-40 peptide from brain by LDL receptorâ€“related protein-1 at the blood-brain barrier. Journal of Clinical Investigation, 2000, 106, 1489-1499.	3.9	1,213
11	Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42in humans. Annals of Neurology, 2006, 59, 512-519.	2.8	1,190
12	Alzheimerâ€™s Disease: The Challenge of the Second Century. Science Translational Medicine, 2011, 3, 77sr1.	5.8	1,109
13	Synaptic Activity Regulates Interstitial Fluid Amyloid-Î² Levels In Vivo. Neuron, 2005, 48, 913-922.	3.8	1,060
14	Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature, 2012, 485, 512-516.	13.7	1,019
15	Human apoE Isoforms Differentially Regulate Brain Amyloid-Î² Peptide Clearance. Science Translational Medicine, 2011, 3, 89ra57.	5.8	924
16	Rapid appearance and local toxicity of amyloid-Î² plaques in a mouse model of Alzheimerâ€™s disease. Nature, 2008, 451, 720-724.	13.7	916
17	Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nature Reviews Neurology, 2018, 14, 168-181.	4.9	905
18	ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature, 2017, 549, 523-527.	13.7	852

#	Article	IF	Citations
19	Cerebrospinal Fluid tau/Î²-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults. Archives of Neurology, 2007, 64, 343.	4.9	841
20	Alzheimer disease. Nature Reviews Disease Primers, 2021, 7, 33.	18.1	784
21	ApoE Promotes the Proteolytic Degradation of AÎ². Neuron, 2008, 58, 681-693.	3.8	779
22	Biomarker Modeling of Alzheimerâ€™s Disease. Neuron, 2013, 80, 1347-1358.	3.8	773
23	Neuronal activity regulates the regional vulnerability to amyloid-Î² deposition. Nature Neuroscience, 2011, 14, 750-756.	7.1	744
24	TREM2 Maintains Microglial Metabolic Fitness in Alzheimerâ€™s Disease. Cell, 2017, 170, 649-663.e13.	13.5	741
25	APOE predicts amyloidâ€beta but not tau Alzheimer pathology in cognitively normal aging. Annals of Neurology, 2010, 67, 122-131.	2.8	727
26	Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurology, The, 2011, 10, 241-252.	4.9	691
27	Sleep and Alzheimer disease pathologyâ€"a bidirectional relationship. Nature Reviews Neurology, 2014, 10, 115-119.	4.9	684
28	Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimerâ€™s disease. Nature Medicine, 2020, 26, 131-142.	15.2	641
29	Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006312-a006312.	2.9	637
30	apoE isoformâ€"specific disruption of amyloid Î² peptide clearance from mouse brain. Journal of Clinical Investigation, 2008, 118, 4002-4013.	3.9	623
31	Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nature Neuroscience, 2015, 18, 800-806.	7.1	582
32	Transport Pathways for Clearance of Human Alzheimer's Amyloid Î²-Peptide and Apolipoproteins E and J in the Mouse Central Nervous System. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 909-918.	2.4	576
33	Sleep Quality and Preclinical Alzheimer Disease. JAMA Neurology, 2013, 70, 587.	4.5	570
34	Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature, 2009, 461, 916-922.	13.7	567
35	TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. Journal of Experimental Medicine, 2016, 213, 667-675.	4.2	565
36	P-glycoprotein deficiency at the blood-brain barrier increases amyloid-Â deposition in an Alzheimer disease mouse model. Journal of Clinical Investigation, 2005, 115, 3285-3290.	3.9	564

#	Article	IF	Citations
37	Tau and Aî² imaging, CSF measures, and cognition in Alzheimerâ€™s disease. Science Translational Medicine, 2016, 8, 338ra66.	5.8	560
38	Brain to Plasma Amyloid-beta Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease. Science, 2002, 295, 2264-2267.	6.0	544
39	Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science, 2016, 354, 1004-1008.	6.0	542
40	Human amyloid-Î² synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nature Medicine, 2006, 12, 856-861.	15.2	537
41	Endocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-Î² In Vivo. Neuron, 2008, 58, 42-51.	3.8	535
42	High-precision plasma Î²-amyloid 42/40 predicts current and future brain amyloidosis. Neurology, 2019, 93, e1647-e1659.	1.5	514
43	Loss of Intranetwork and Internetwork Resting State Functional Connections with Alzheimer's Disease Progression. Journal of Neuroscience, 2012, 32, 8890-8899.	1.7	510
44	Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. Journal of Neurochemistry, 2001, 77, 1168-1180.	2.1	505
45	Trans-cellular Propagation of Tau Aggregation by Fibrillar Species. Journal of Biological Chemistry, 2012, 287, 19440-19451.	1.6	483
46	Anti-Tau Antibodies that Block Tau Aggregate Seeding InÂVitro Markedly Decrease Pathology and Improve Cognition InÂVivo. Neuron, 2013, 80, 402-414.	3.8	483
47	Proteopathic tau seeding predicts tauopathy in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4376-85.	3.3	474
48	Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurology, The, 2013, 12, 957-965.	4.9	471
49	Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimerâ€™s disease. Scientific Reports, 2016, 6, 30028.	1.6	469
50	BDNF Protects the Neonatal Brain from Hypoxic-Ischemic InjuryIn Vivovia the ERK Pathway. Journal of Neuroscience, 2000, 20, 5775-5781.	1.7	465
51	The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science, 2019, 363, 880-884.	6.0	460
52	Disruption of the Sleep-Wake Cycle and Diurnal Fluctuation of Î²-Amyloid in Mice with Alzheimerâ€™s Disease Pathology. Science Translational Medicine, 2012, 4, 150ra122.	5.8	454
53	Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease. Archives of Neurology, 2009, 66, 1469-75.	4.9	434
54	Neuronal activity regulates extracellular tau in vivo. Journal of Experimental Medicine, 2014, 211, 387-393.	4.2	429

#	Article	IF	Citations
55	ApoE influences amyloid-Î² (AÎ²) clearance despite minimal apoE/AÎ² association in physiological conditions. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1807-16.	3.3	428
56	Amyloid Î² concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer's and Dementia, 2017, 13, 841-849.	0.4	423
57	In VivoAssessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-Î² Metabolism and Half-Life. Journal of Neuroscience, 2003, 23, 8844-8853.	1.7	414
58	ApoE and Clusterin Cooperatively Suppress AÎ² Levels and Deposition. Neuron, 2004, 41, 193-202.	3.8	411
59	Slow wave sleep disruption increases cerebrospinal fluid amyloid-Î² levels. Brain, 2017, 140, 2104-2111.	3.7	401
60	Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nature Reviews Immunology, 2018, 18, 759-772.	10.6	394
61	p140trk mRNA marks NGF-responsive forebrain neurons: Evidence that trk gene expression is induced by NGF. Neuron, 1992, 9, 465-478.	3.8	383
62	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurology, The, 2018, 17, 241-250.	4.9	383
63	YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease. Biological Psychiatry, 2010, 68, 903-912.	0.7	382
64	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. Annals of Neurology, 2016, 79, 929-939.	2.8	381
65	ABCA1 Is Required for Normal Central Nervous System ApoE Levels and for Lipidation of Astrocyte-secreted apoE. Journal of Biological Chemistry, 2004, 279, 40987-40993.	1.6	376
66	Sleep, circadian rhythms, and the pathogenesis of Alzheimer Disease. Experimental and Molecular Medicine, 2015, 47, e148-e148.	3.2	375
67	Microglia Mediate the Clearance of Soluble AÎ² through Fluid Phase Macropinocytosis. Journal of Neuroscience, 2009, 29, 4252-4262.	1.7	362
68	Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nature Neuroscience, 2019, 22, 191-204.	7.1	358
69	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.4	354
70	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
71	GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimerâ€™s Disease. Neuron, 2013, 78, 256-268.	3.8	344
72	TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 11524-11529.	3.3	328

#	Article	IF	Citations
73	Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimerâ€™s Disease. Science Translational Medicine, 2014, 6, 226ra30.	5.8	320
74	Functional connectivity and graph theory in preclinical Alzheimer's disease. Neurobiology of Aging, 2014, 35, 757-768.	1.5	318
75	Cerebrospinal fluid tau and ptau ₁₈₁ increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. EMBO Molecular Medicine, 2009, 1, 371-380.	3.3	315
76	A Î³â€secretase inhibitor decreases amyloidâ€Î² production in the central nervous system. Annals of Neurology, 2009, 66, 48-54.	2.8	314
77	Expression of human apolipoprotein E reduces amyloid-Î² deposition in a mouse model of Alzheimer's disease. Journal of Clinical Investigation, 1999, 103, R15-R21.	3.9	311
78	Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid Â. Journal of Neuroscience, 2005, 25, 629-636.	1.7	309
79	In VivoMicrodialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice. Journal of Neuroscience, 2011, 31, 13110-13117.	1.7	309
80	Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10843-10848.	3.3	308
81	Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Annals of Neurology, 2002, 52, 54-61.	2.8	308
82	Decreased cerebrospinal fluid AÎ²₄₂ correlates with brain atrophy in cognitively normal elderly. Annals of Neurology, 2009, 65, 176-183.	2.8	307
83	Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. Journal of Clinical Investigation, 2008, 118, 671-82.	3.9	301
84	Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease. Neurobiology of Disease, 2006, 24, 506-515.	2.1	299
85	Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Annals of Neurology, 2000, 47, 739-747.	2.8	293
86	Deletion of Abca1 Increases AÎ² Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease. Journal of Biological Chemistry, 2005, 280, 43236-43242.	1.6	288
87	New insights into the role of TREM2 in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2018, 13, 66.	4.4	286
88	Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease. JAMA Neurology, 2018, 75, 582.	4.5	285
89	Glial contributions to neurodegeneration in tauopathies. Molecular Neurodegeneration, 2017, 12, 50.	4.4	283
90	Bidirectional relationship between sleep and Alzheimerâ€™s disease: role of amyloid, tau, and other factors. Neuropsychopharmacology, 2020, 45, 104-120.	2.8	280

#	Article	IF	Citations
91	Role of Tissue Plasminogen Activator Receptor LRP in Hippocampal Long-Term Potentiation. Journal of Neuroscience, 2000, 20, 542-549.	1.7	277
92	Amyloid-Î² Dynamics Correlate with Neurological Status in the Injured Human Brain. Science, 2008, 321, 1221-1224.	6.0	270
93	Apolipoprotein E4 effects in Alzheimerâ€™s disease are mediated by synaptotoxic oligomeric amyloid-Î². Brain, 2012, 135, 2155-2168.	3.7	268
94	Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Annals of Neurology, 2010, 68, 311-318.	2.8	263
95	Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathologica, 2016, 131, 925-933.	3.9	262
96	Altered microglial response to AÎ² plaques in APPPS1-21 mice heterozygous for TREM2. Molecular Neurodegeneration, 2014, 9, 20.	4.4	257
97	Elucidating the Role of TREM2 in Alzheimerâ€™s Disease. Neuron, 2017, 94, 237-248.	3.8	255
98	Antisense Reduction of Tau in Adult Mice Protects against Seizures. Journal of Neuroscience, 2013, 33, 12887-12897.	1.7	254
99	BDNF Blocks Caspase-3 Activation in Neonatal Hypoxiaâ€“Ischemia. Neurobiology of Disease, 2000, 7, 38-53.	2.1	251
100	Human and Murine ApoE Markedly Alters AÎ² Metabolism before and after Plaque Formation in a Mouse Model of Alzheimer's Disease. Neurobiology of Disease, 2002, 9, 305-318.	2.1	248
101	Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. Journal of Experimental Medicine, 2019, 216, 2546-2561.	4.2	244
102	Human Apolipoprotein E4 Alters the Amyloid-Â 40:42 Ratio and Promotes the Formation of Cerebral Amyloid Angiopathy in an Amyloid Precursor Protein Transgenic Model. Journal of Neuroscience, 2005, 25, 2803-2810.	1.7	243
103	Î±₂â€Macroglobulin Complexes with and Mediates the Endocytosis of Î²â€Amyloid Peptide via Cell Surface Lowâ€Density Lipoprotein Receptorâ€Related Protein. Journal of Neurochemistry, 1997, 69, 1904-1911.	2.1	237
104	Active and Passive Immunotherapy for Neurodegenerative Disorders. Annual Review of Neuroscience, 2008, 31, 175-193.	5.0	237
105	Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurology, 2015, 72, 1029.	4.5	237
106	Fluctuations of CSF amyloid-ss levels: Implications for a diagnostic and therapeutic biomarker. Neurology, 2007, 68, 666-669.	1.5	233
107	Bcl-x_Lis an Antiapoptotic Regulator for Postnatal CNS Neurons. Journal of Neuroscience, 1998, 18, 1009-1019.	1.7	232
108	Characterizing the Appearance and Growth of Amyloid Plaques in APP/PS1 Mice. Journal of Neuroscience, 2009, 29, 10706-10714.	1.7	230

#	Article	IF	Citations
109	Plaque-associated disruption of CSF and plasma amyloid-Î² (AÎ²) equilibrium in a mouse model of Alzheimer's disease. Journal of Neurochemistry, 2002, 81, 229-236.	2.1	228
110	Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. JAMA Neurology, 2019, 76, 264.	4.5	227
111	Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid Î² Peptide. Journal of Neuroscience, 2012, 32, 15181-15192.	1.7	219
112	Nitric Oxide Mediates Cerebral Ischemic Tolerance in a Neonatal Rat Model of Hypoxic Preconditioning. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 331-340.	2.4	212
113	Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular AÎ² Clearance. Neuron, 2009, 64, 632-644.	3.8	212
114	Glial Fibrillary Acidic Proteinâ€“Apolipoprotein E (apoE) Transgenic Mice: Astrocyte-Specific Expression and Differing Biological Effects of Astrocyte-Secreted apoE3 and apoE4 Lipoproteins. Journal of Neuroscience, 1998, 18, 3261-3272.	1.7	211
115	Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology, 2012, 79, 897-905.	1.5	208
116	Reduced nonâ€“rapid eye movement sleep is associated with tau pathology in early Alzheimerâ€™s disease. Science Translational Medicine, 2019, 11, .	5.8	208
117	Neuronal Clearance of Amyloid-Î² by Endocytic Receptor LRP1. Journal of Neuroscience, 2013, 33, 19276-19283.	1.7	206
118	Apolipoprotein E-containing High Density Lipoprotein Promotes Neurite Outgrowth and Is a Ligand for the Low Density Lipoprotein Receptor-related Protein. Journal of Biological Chemistry, 1996, 271, 30121-30125.	1.6	199
119	Genome-wide association study identifies four novel loci associated with Alzheimerâ€™s endophenotypes and disease modifiers. Acta Neuropathologica, 2017, 133, 839-856.	3.9	199
120	Clusterin contributes to caspase-3â€“independent brain injury following neonatal hypoxia-ischemia. Nature Medicine, 2001, 7, 338-343.	15.2	196
121	Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Human Molecular Genetics, 2012, 21, 4558-4571.	1.4	196
122	Increased in Vivo Amyloid-Î²42 Production, Exchange, and Loss in Presenilin Mutation Carriers. Science Translational Medicine, 2013, 5, 189ra77.	5.8	196
123	Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis. PLoS ONE, 2011, 6, e18850.	1.1	196
124	Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer Type. Archives of Neurology, 2009, 66, 638-45.	4.9	194
125	Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology, 2013, 80, 1784-1791.	1.5	194
126	ApoE facilitates the microglial response to amyloid plaque pathology. Journal of Experimental Medicine, 2018, 215, 1047-1058.	4.2	194

#	Article	IF	Citations
127	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology, 2018, 91, e1295-e1306.	1.5	193
128	Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimer's and Dementia, 2018, 14, 1460-1469.	0.4	192
129	Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 10673-10678.	3.3	190
130	TREM2 function impedes tau seeding in neuritic plaques. Nature Neuroscience, 2019, 22, 1217-1222.	7.1	190
131	Potential role of orexin and sleep modulation in the pathogenesis of Alzheimerâ€™s disease. Journal of Experimental Medicine, 2014, 211, 2487-2496.	4.2	189
132	Absence of Pittsburgh Compound B Detection of Cerebral Amyloid Î² in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease. Archives of Neurology, 2009, 66, 1557-62.	4.9	188
133	Chronic Optogenetic Activation Augments AÎ² Pathology in a Mouse Model of Alzheimer Disease. Cell Reports, 2015, 11, 859-865.	2.9	186
134	TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. Acta Neuropathologica, 2020, 140, 513-534.	3.9	186
135	Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. JAMA Neurology, 2015, 72, 1275.	4.5	183
136	Unique Lipoproteins Secreted by Primary Astrocytes From Wild Type, apoE (â^'/â^'), and Human apoE Transgenic Mice. Journal of Biological Chemistry, 1999, 274, 30001-30007.	1.6	182
137	Lipoproteins in the Central Nervous System. Annals of the New York Academy of Sciences, 2000, 903, 167-175.	1.8	182
138	Neonatal Mice Lacking Neuronal Nitric Oxide Synthase Are Less Vulnerable to Hypoxicâ€“Ischemic Injury. Neurobiology of Disease, 1996, 3, 64-71.	2.1	181
139	Developing an international network for Alzheimerâ€™s research: the Dominantly Inherited Alzheimer Network. Clinical Investigation, 2012, 2, 975-984.	0.0	180
140	Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10186-10191.	3.3	179
141	Meningeal lymphatics affect microglia responses and anti-AÎ² immunotherapy. Nature, 2021, 593, 255-260.	13.7	179
142	Biomarkers of Alzheimer's disease. Neurobiology of Disease, 2009, 35, 128-140.	2.1	175
143	Astrocytic LRP1 Mediates Brain AÎ² Clearance and Impacts Amyloid Deposition. Journal of Neuroscience, 2017, 37, 4023-4031.	1.7	175
144	Marked age-dependent neuroprotection by brain-derived neurotrophic factor against neonatal hypoxic?ischemic brain injury. Annals of Neurology, 1997, 41, 521-529.	2.8	171

#	Article	IF	Citations
145	BDNF Protects against Spatial Memory Deficits Following Neonatal Hypoxia-Ischemia. Experimental Neurology, 2000, 166, 99-114.	2.0	169
146	Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. Molecular Neurodegeneration, 2016, 11, 74.	4.4	168
147	Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-Î² Amyloidosis. Journal of Neuroscience, 2011, 31, 18007-18012.	1.7	166
148	Bidirectional Relationship between Functional Connectivity and Amyloid-Î² Deposition in Mouse Brain. Journal of Neuroscience, 2012, 32, 4334-4340.	1.7	165
149	Hyperglycemia modulates extracellular amyloid-Î² concentrations and neuronal activity in vivo. Journal of Clinical Investigation, 2015, 125, 2463-2467.	3.9	165
150	Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury. Experimental Neurology, 2006, 197, 330-340.	2.0	164
151	Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-Î²42 by LRP1-dependent apolipoprotein E isoform-specific mechanism. Molecular Neurodegeneration, 2018, 13, 57.	4.4	164
152	Selective, Reversible Caspase-3 Inhibitor Is Neuroprotective and Reveals Distinct Pathways of Cell Death after Neonatal Hypoxic-ischemic Brain Injury. Journal of Biological Chemistry, 2002, 277, 30128-30136.	1.6	163
153	Role of the Menkes copper-transporting ATPase in NMDA receptor-mediated neuronal toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14919-14924.	3.3	161
154	Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of Î²-Amyloid 1-42, Total tau, and P-tau‹sub›181‹/sub› for Identifying Alzheimer Disease Amyloid Plaque Pathology. Archives of Neurology, 2011, 68, 1137.	4.9	161
155	Anti-AÎ² antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. Journal of Clinical Investigation, 2005, 115, 428-433.	3.9	161
156	Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-Î² and other amyloidogenic proteins. Journal of Lipid Research, 2017, 58, 824-836.	2.0	159
157	Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. JAMA Neurology, 2016, 73, 561.	4.5	154
158	Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. Neurochemistry International, 2001, 39, 415-425.	1.9	153
159	Changes in insulin and insulin signaling in Alzheimerâ€™s disease: cause or consequence?. Journal of Experimental Medicine, 2016, 213, 1375-1385.	4.2	153
160	Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease. PLoS ONE, 2011, 6, e16032.	1.1	152
161	Low-density Lipoprotein Receptor Represents an Apolipoprotein E-independent Pathway of AÎ² Uptake and Degradation by Astrocytes. Journal of Biological Chemistry, 2012, 287, 13959-13971.	1.6	152
162	Evidence for peripheral clearance of cerebral AÎ² protein following chronic, active AÎ² immunization in PSAPP mice. Neurobiology of Disease, 2003, 14, 10-18.	2.1	151

#	Article	IF	Citations
163	The Choroid Plexus and Cerebrospinal Fluid: Emerging Roles in Development, Disease, and Therapy. Journal of Neuroscience, 2013, 33, 17553-17559.	1.7	151
164	Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron, 2021, 109, 1657-1674.e7.	3.8	151
165	Tau elevations in the brain extracellular space correlate with reduced amyloid-Î² levels and predict adverse clinical outcomes after severe traumatic brain injury. Brain, 2012, 135, 1268-1280.	3.7	150
166	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain, 2016, 139, 2249-2260.	3.7	150
167	Age and amyloid effects on human central nervous system amyloidâ€beta kinetics. Annals of Neurology, 2015, 78, 439-453.	2.8	148
168	Nerve growth factor protects the neonatal brain against hypoxic-ischemic injury. Annals of Neurology, 1996, 39, 114-122.	2.8	147
169	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology, 2021, 78, 396.	4.5	146
170	Antiâ€tau antibody reduces insoluble tau and decreases brain atrophy. Annals of Clinical and Translational Neurology, 2015, 2, 278-288.	1.7	145
171	Deciphering Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a011460-a011460.	2.9	143
172	In Situ Immunodetection of Neuronal Caspase-3 Activation in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 1999, 58, 1020-1026.	0.9	142
173	A Synthetic Peptide Blocking the Apolipoprotein E/Î²-Amyloid Binding Mitigates Î²-Amyloid Toxicity and Fibril Formation in Vitro and Reduces Î²-Amyloid Plaques in Transgenic Mice. American Journal of Pathology, 2004, 165, 937-948.	1.9	141
174	Dietary salt promotes cognitive impairment through tau phosphorylation. Nature, 2019, 574, 686-690.	13.7	140
175	Apolipoprotein E Markedly Facilitates Age-Dependent Cerebral Amyloid Angiopathy and Spontaneous Hemorrhage in Amyloid Precursor Protein Transgenic Mice. Journal of Neuroscience, 2003, 23, 7889-7896.	1.7	139
176	Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis. Neuron, 2021, 109, 205-221.	3.8	139
177	Impact of TREM2R47H variant on tau pathologyâ€“induced gliosis and neurodegeneration. Journal of Clinical Investigation, 2020, 130, 4954-4968.	3.9	139
178	Maternal Dietary Supplementation with Pomegranate Juice Is Neuroprotective in an Animal Model of Neonatal Hypoxic-Ischemic Brain Injury. Pediatric Research, 2005, 57, 858-864.	1.1	138
179	Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood AÎ² clearance in a mouse model of Î²-amyloidosis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15502-15507.	3.3	138
180	Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	138

#	Article	IF	Citations
181	Pomegranate Polyphenols and Resveratrol Protect the Neonatal Brain against Hypoxic-Ischemic Injury. Developmental Neuroscience, 2007, 29, 363-372.	1.0	137
182	Rapid Microglial Response Around Amyloid Pathology after Systemic Anti-Aî² Antibody Administration in PDAPP Mice. Journal of Neuroscience, 2008, 28, 14156-14164.	1.7	136
183	Treatment with an Amyloid-Â Antibody Ameliorates Plaque Load, Learning Deficits, and Hippocampal Long-Term Potentiation in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2005, 25, 6213-6220.	1.7	135
184	Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of Î²-amyloidosis. Neuron, 2017, 96, 1013-1023.e4.	3.8	134
185	Dural lymphatics regulate clearance of extracellular tau from the CNS. Molecular Neurodegeneration, 2019, 14, 11.	4.4	134
186	A Role for TrkA during Maturation of Striatal and Basal Forebrain Cholinergic NeuronsIn Vivo. Journal of Neuroscience, 1997, 17, 7644-7654.	1.7	133
187	Visininâ€like proteinâ€1: Diagnostic and prognostic biomarker in Alzheimer disease. Annals of Neurology, 2011, 70, 274-285.	2.8	132
188	Lysosomal Sorting of Amyloid-Î² by the SORLA Receptor Is Impaired by a Familial Alzheimerâ€™s Disease Mutation. Science Translational Medicine, 2014, 6, 223ra20.	5.8	131
189	A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. Alzheimer's Research and Therapy, 2019, 11, 71.	3.0	131
190	Increased soluble amyloid-Â peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1075-1080.	3.3	128
191	ole of apoE/Aî² Interactions in the Pathogenesis of Alzheimer's Disease and Cerebral Amyloid Angiopathy. Journal of Molecular Neuroscience, 2001, 17, 147-155.	1.1	127
192	Differences in the A?40/A?42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Annals of Neurology, 2000, 48, 201-210.	2.8	126
193	Sleep in Alzheimer's Diseaseâ€“Beyond Amyloid. Neurobiology of Sleep and Circadian Rhythms, 2017, 2, 4-14.	1.4	126
194	Regulation of amyloid-Î² dynamics and pathology by the circadian clock. Journal of Experimental Medicine, 2018, 215, 1059-1068.	4.2	123
195	BAX Contributes to Apoptotic-Like Death Following Neonatal Hypoxia-Ischemia: Evidence for Distinct Apoptosis Pathways. Molecular Medicine, 2001, 7, 644-655.	1.9	121
196	In Vivo Effects of ApoE and Clusterin on Amyloid-Î² Metabolism and Neuropathology. Journal of Molecular Neuroscience, 2004, 23, 247-254.	1.1	121
197	Comparative Proteomic Analysis of Intra- and Interindividual Variation in Human Cerebrospinal Fluid. Molecular and Cellular Proteomics, 2005, 4, 2000-2009.	2.5	121
198	The Low Density Lipoprotein Receptor Regulates the Level of CentralNervous System Human and Murine Apolipoprotein E but Does Not Modify AmyloidPlaque Pathology in PDAPPMice. Journal of Biological Chemistry, 2005, 280, 25754-25759.	1.6	121

#	Article	IF	Citations
199	Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of AÎ² amyloidosis. Journal of Experimental Medicine, 2012, 209, 2149-2156.	4.2	120
200	ApoE Cascade Hypothesis in the pathogenesis of Alzheimerâ€™s disease and related dementias. Neuron, 2022, 110, 1304-1317.	3.8	120
201	ApoE4 upregulates the activity of mitochondriaâ€associated ER membranes. EMBO Reports, 2016, 17, 27-36.	2.0	119
202	The sleepâ€“wake cycle and Alzheimer's disease: what do we know?. Neurodegenerative Disease Management, 2014, 4, 351-362.	1.2	118
203	Apolipoprotein E and Low Density Lipoprotein Receptor-related Protein Facilitate Intraneuronal AÎ²42 Accumulation in Amyloid Model Mice. Journal of Biological Chemistry, 2006, 281, 36180-36186.	1.6	117
204	Cerebrovascular Dysfunction in Amyloid Precursor Protein Transgenic Mice: Contribution of Soluble and Insoluble Amyloid-Î² Peptide, Partial Restoration via Î³-Secretase Inhibition. Journal of Neuroscience, 2008, 28, 13542-13550.	1.7	117
205	Tau: From research to clinical development. Alzheimer's and Dementia, 2016, 12, 1033-1039.	0.4	117
206	Obstructive sleep apnea decreases central nervous systemâ€“derived proteins in the cerebrospinal fluid. Annals of Neurology, 2016, 80, 154-159.	2.8	117
207	Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-Î² clearance and aggregation in Alzheimerâ€™s disease. Science Translational Medicine, 2016, 8, 332ra44.	5.8	115
208	Amyloid-Î² and Tau at theÂCrossroads of Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2019, 1184, 187-203.	0.8	115
209	Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Annals of Neurology, 2003, 54, 115-119.	2.8	113
210	Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 869-879.	0.4	113
211	Novel Role for Apolipoprotein E in the Central Nervous System. Journal of Biological Chemistry, 2003, 278, 8043-8051.	1.6	112
212	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1111.	4.5	112
213	Role of caspase-3 in ethanol-induced developmental neurodegeneration. Neurobiology of Disease, 2005, 20, 608-614.	2.1	111
214	SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease. PLoS Genetics, 2010, 6, e1001101.	1.5	111
215	Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimerâ€™s disease pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11965-11970.	3.3	111
216	Evidence for Normal Aging of the Septo-Hippocampal Cholinergic System in apoE (â^'/â^') Mice but Impaired Clearance of Axonal Degeneration Products Following Injury. Experimental Neurology, 1998, 151, 314-325.	2.0	110

#	Article	IF	Citations
217	Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-Î². Neurobiology of Disease, 2005, 19, 66-76.	2.1	110
218	Missense variant in TREML2 protects against Alzheimer's disease. Neurobiology of Aging, 2014, 35, 1510.e19-1510.e26.	1.5	110
219	Genome-Wide Association Study of CSF Levels of 59 Alzheimer's Disease Candidate Proteins: Significant Associations with Proteins Involved in Amyloid Processing and Inflammation. PLoS Genetics, 2014, 10, e1004758.	1.5	109
220	Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E881-90.	3.3	109
221	A spectrum of exercise training reduces soluble AÎ² in a dose-dependent manner in a mouse model of Alzheimer's disease. Neurobiology of Disease, 2016, 85, 218-224.	2.1	109
222	Polygenic risk score of sporadic lateâ€onset Alzheimer's disease reveals a shared architecture with the familial and earlyâ€onset forms. Alzheimer's and Dementia, 2018, 14, 205-214.	0.4	109
223	Apolipoprotein E4 Influences Amyloid Deposition But Not Cell Loss after Traumatic Brain Injury in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2002, 22, 10083-10087.	1.7	108
224	Effect of Different Anti-AÎ² Antibodies on AÎ² Fibrillogenesis as Assessed by Atomic Force Microscopy. Journal of Molecular Biology, 2004, 335, 997-1006.	2.0	105
225	Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. Journal of Clinical Investigation, 2018, 128, 2144-2155.	3.9	105
226	microRNA-33 Regulates ApoE Lipidation and Amyloid-Î² Metabolism in the Brain. Journal of Neuroscience, 2015, 35, 14717-14726.	1.7	104
227	Comparison of a singleâ€channel <scp>EEG</scp> sleep study to polysomnography. Journal of Sleep Research, 2016, 25, 625-635.	1.7	104
228	Alzheimer Disease in 2020. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a011585-a011585.	2.9	103
229	In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Molecular Neurodegeneration, 2013, 8, 13.	4.4	103
230	Anti-ApoE Antibody Given after Plaque Onset Decreases AÎ² Accumulation and Improves Brain Function in a Mouse Model of AÎ² Amyloidosis. Journal of Neuroscience, 2014, 34, 7281-7292.	1.7	102
231	APOE genotype regulates pathology and disease progression in synucleinopathy. Science Translational Medicine, 2020, 12, .	5.8	102
232	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimerâ€™s disease in a memory clinic cohort. Alzheimer's Research and Therapy, 2015, 7, 59.	3.0	101
233	Distinct Therapeutic Mechanisms of Tau Antibodies. Journal of Biological Chemistry, 2015, 290, 21652-21662.	1.6	100
234	TREM2 Function in Alzheimerâ€™s Disease and Neurodegeneration. ACS Chemical Neuroscience, 2016, 7, 420-427.	1.7	100

#	Article	IF	Citations
235	Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE Îµ4 genotype. Brain, 2018, 141, 1828-1839.	3.7	99
236	Intercellular Spread of Protein Aggregates in Neurodegenerative Disease. Annual Review of Cell and Developmental Biology, 2018, 34, 545-568.	4.0	99
237	A blood-based diagnostic test incorporating plasma AÎ²42/40 ratio, ApoE proteotype, and age accurately identifiesÂbrain amyloid status: findings from a multi cohort validity analysis. Molecular Neurodegeneration, 2021, 16, 30.	4.4	98
238	Association and Expression Analyses With Single-Nucleotide Polymorphisms in <emph type="ital">TOMM40</emph> in Alzheimer Disease. Archives of Neurology, 2011, 68, 1013.	4.9	97
239	CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiology of Aging, 2011, 32, S4-S9.	1.5	96
240	The Binding of Apolipoprotein E to Oligomers and Fibrils of Amyloid-Î² Alters the Kinetics of Amyloid Aggregation. Biochemistry, 2014, 53, 6323-6331.	1.2	96
241	Trisomy of human chromosome 21 enhances amyloid-Î² deposition independently of an extra copy ofAPP. Brain, 2018, 141, 2457-2474.	3.7	96
242	Dynamic Analysis of Amyloid Î²-Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal AÎ² during Age-Related Plaque Formation. Journal of Neuroscience, 2011, 31, 15861-15869.	1.7	95
243	Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. American Journal of Geriatric Psychiatry, 2016, 24, 1095-1104.	0.6	95
244	Impaired Autophagy in APOE4 Astrocytes. Journal of Alzheimer's Disease, 2016, 51, 915-927.	1.2	94
245	Activated microglia mitigate AÎ²-associated tau seeding and spreading. Journal of Experimental Medicine, 2021, 218, .	4.2	94
246	SOD1 in Cerebral Spinal Fluid as a Pharmacodynamic Marker for Antisense Oligonucleotide Therapy. JAMA Neurology, 2013, 70, 201.	4.5	93
247	Extreme cerebrospinal fluid amyloid Î² levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Annals of Neurology, 2007, 61, 446-453.	2.8	87
248	Translational profiling of hypocretin neurons identifies candidate molecules for sleep regulation. Genes and Development, 2013, 27, 565-578.	2.7	87
249	The Lowâ€Density Lipoprotein Receptorâ€Related Protein, a Multifunctional Apolipoprotein E Receptor, Modulates Hippocampal Neurite Development. Journal of Neurochemistry, 1997, 68, 587-595.	2.1	86
250	Highâ€affinity interactions and signal transduction between AÎ² oligomers and <scp>TREM</scp> 2. EMBO Molecular Medicine, 2018, 10, .	3.3	86
251	Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8050-8054.	3.3	84
252	Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. Annals of Neurology, 2016, 80, 379-387.	2.8	82

#	Article	IF	Citations
253	NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiology of Aging, 2016, 44, 1-8.	1.5	80
254	Amyloid Î²40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. Journal of Alzheimer's Disease, 2001, 3, 23-30.	1.2	79
255	Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Science Translational Medicine, 2017, 9, .	5.8	78
256	C9orf72 deficiency promotes microglial-mediated synaptic loss in aging and amyloid accumulation. Neuron, 2021, 109, 2275-2291.e8.	3.8	78
257	Longitudinal Î²-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Nonâ€“Alzheimer Disease Pathophysiology. JAMA Neurology, 2016, 73, 1192.	4.5	77
258	Altered sleep and EEG power in the P301S Tau transgenic mouse model. Annals of Clinical and Translational Neurology, 2017, 4, 180-190.	1.7	76
259	Lack of hepatic apoE does not influence early AÎ² deposition: observations from a new APOE knock-in model. Molecular Neurodegeneration, 2019, 14, 37.	4.4	76
260	APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Science Translational Medicine, 2021, 13, .	5.8	76
261	Astrocyte lipoproteins, effects of apoE on neuronal function, and role of apoE in amyloid-? deposition in vivo. Microscopy Research and Technique, 2000, 50, 297-304.	1.2	75
262	Aerobic Glycolysis in the Frontal Cortex Correlates with Memory Performance in Wild-Type Mice But Not the APP/PS1 Mouse Model of Cerebral Amyloidosis. Journal of Neuroscience, 2016, 36, 1871-1878.	1.7	75
263	Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. JAMA Neurology, 2015, 72, 656.	4.5	74
264	Phosphorylated Tau-AÎ²42 Ratio as a Continuous Trait for Biomarker Discovery for Early-Stage Alzheimerâ€™s Disease in Multiplex Immunoassay Panels of Cerebrospinal Fluid. Biological Psychiatry, 2014, 75, 723-731.	0.7	72
265	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 655-665.	0.4	72
266	Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer's disease. Neurobiology of Aging, 2010, 31, 1188-1196.	1.5	70
267	Blocking the Interaction between Apolipoprotein E and AÎ² Reduces Intraneuronal Accumulation of AÎ² and Inhibits Synaptic Degeneration. American Journal of Pathology, 2013, 182, 1750-1768.	1.9	70
268	BDNFVal66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimerâ€™s disease. Brain, 2016, 139, 2766-2777.	3.7	70
269	Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Molecular Neurodegeneration, 2007, 2, 7.	4.4	68
270	Obstructive sleep apnea treatment, slow wave activity, and amyloidâ€Î². Annals of Neurology, 2019, 85, 291-295.	2.8	68

#	Article	IF	Citations
271	TFEB regulates lysosomal exocytosis of tau and its loss of function exacerbates tau pathology and spreading. Molecular Psychiatry, 2021, 26, 5925-5939.	4.1	68
272	Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. Proteomics - Clinical Applications, 2007, 1, 1373-1384.	0.8	66
273	Modeling Sporadic Alzheimer's Disease in Human Brain Organoids under Serum Exposure. Advanced Science, 2021, 8, e2101462.	5.6	66
274	Cerebrospinal fluid biomarkers of Alzheimerâ€™s disease. Biomarkers in Medicine, 2010, 4, 51-63.	0.6	65
275	Fine Mapping of Genetic Variants in BIN1, CLU, CR1 and PICALM for Association with Cerebrospinal Fluid Biomarkers for Alzheimer's Disease. PLoS ONE, 2011, 6, e15918.	1.1	64
276	Sleep and longitudinal cognitive performance in preclinical and early symptomatic Alzheimerâ€™s disease. Brain, 2021, 144, 2852-2862.	3.7	62
277	Gut Microbiota: From the Forgotten Organ to a Potential Key Player in the Pathology of Alzheimerâ€™s Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1232-1241.	1.7	61
278	Analysis of in vivo turnover of tau in a mouse model of tauopathy. Molecular Neurodegeneration, 2015, 10, 55.	4.4	60
279	PDAPP; YFP double transgenic mice: A tool to study amyloid-? associated changes in axonal, dendritic, and synaptic structures. Journal of Comparative Neurology, 2003, 456, 375-383.	0.9	59
280	Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models. Neurobiology of Aging, 2016, 44, 159-172.	1.5	59
281	Opposing Synaptic Regulation of Amyloid-Î² Metabolism by NMDA ReceptorsIn Vivo. Journal of Neuroscience, 2011, 31, 11328-11337.	1.7	58
282	The Effects of Peripheral and Central High Insulin on Brain Insulin Signaling and Amyloid-Î² in Young and Old APP/PS1 Mice. Journal of Neuroscience, 2016, 36, 11704-11715.	1.7	58
283	APOE mediated neuroinflammation and neurodegeneration in Alzheimerâ€™s disease. Seminars in Immunology, 2022, 59, 101594.	2.7	58
284	AÎ² immunization and anti-AÎ² antibodies: potential therapies for the prevention and treatment of Alzheimerâ€™s disease. Advanced Drug Delivery Reviews, 2002, 54, 1603-1613.	6.6	57
285	Biomarkers in translational research of Alzheimerâ€™s Disease. Neuropharmacology, 2010, 59, 310-322.	2.0	57
286	Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. Neurobiology of Aging, 2017, 56, 25-32.	1.5	57
287	25-Hydroxycholesterol amplifies microglial IL-1Î² production in an apoE isoform-dependent manner. Journal of Neuroinflammation, 2020, 17, 192.	3.1	57
288	Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms. Neuron, 2021, 109, 2413-2426.e7.	3.8	57

#	Article	IF	Citations
289	NOS induction by NGF in basal forebrain cholinergic neurones: evidence for regulation of brain NOS by a neurotrophin. Neurobiology of Disease, 1994, 1, 51-60.	2.1	56
290	Role of nerve growth factor in experimental autoimmune encephalomyelitis. European Journal of Immunology, 2001, 31, 625-633.	1.6	55
291	The PSEN1, p.E318G Variant Increases the Risk of Alzheimer's Disease in APOE-Îµ4 Carriers. PLoS Genetics, 2013, 9, e1003685.	1.5	55
292	ApoAI Deficiency Results in Marked Reductions in Plasma Cholesterol But No Alterations in Amyloid-Î² Pathology in a Mouse Model of Alzheimer's Disease-Like Cerebral Amyloidosis. American Journal of Pathology, 2004, 165, 1413-1422.	1.9	52
293	Nicotinamide mononucleotide adenylyl transferase 1 protects against acute neurodegeneration in developing CNS by inhibiting excitotoxic-necrotic cell death. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19054-19059.	3.3	52
294	Caspases: A treatment target for neurodegenerative disease?. Nature Medicine, 1997, 3, 954-955.	15.2	51
295	A randomized controlled study to evaluate the effect of bexarotene on amyloidâ€Î² and apolipoprotein E metabolism in healthy subjects. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 110-120.	1.8	51
296	Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9665-E9674.	3.3	51
297	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimerâ€™s disease. PLoS ONE, 2018, 13, e0195838.	1.1	51
298	Current thinking on the mechanistic basis of Alzheimer's and implications for drug development. Clinical Pharmacology and Therapeutics, 2015, 98, 469-471.	2.3	50
299	Upward drift in cerebrospinal fluid amyloid Î² 42 assay values for more than 10Âyears. Alzheimer's and Dementia, 2018, 14, 62-70.	0.4	50
300	Behavioral and transcriptomic analysis of Trem2-null mice: not all knockout mice are created equal. Human Molecular Genetics, 2018, 27, 211-223.	1.4	50
301	Caspase-3 deficiency during development increases vulnerability to hypoxicâ€“ischemic injury through caspase-3-independent pathways. Neurobiology of Disease, 2006, 22, 523-537.	2.1	48
302	Traumatic brain injury reduces soluble extracellular amyloid-Î² in mice: A methodologically novel combined microdialysis-controlled cortical impact study. Neurobiology of Disease, 2010, 40, 555-564.	2.1	48
303	Quantitative Label-Free Proteomics for Discovery of Biomarkers in Cerebrospinal Fluid: Assessment of Technical and Inter-Individual Variation. PLoS ONE, 2013, 8, e64314.	1.1	47
304	How amyloid, sleep and memory connect. Nature Neuroscience, 2015, 18, 933-934.	7.1	46
305	Toward a multifactorial model of Alzheimer disease. Neurobiology of Aging, 2012, 33, 2262-2271.	1.5	45
306	Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. Acta Neuropathologica Communications, 2015, 3, 70.	2.4	45

#	Article	IF	Citations
307	AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. Journal of Experimental Medicine, 2017, 214, 1227-1238.	4.2	45
308	A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin. Neurobiology of Aging, 2016, 37, 208.e1-208.e9.	1.5	44
309	Preclinical Alzheimer's disease and longitudinal driving decline. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 74-82.	1.8	44
310	Selective reduction of astrocyte apoE3 and apoE4 strongly reduces AÎ² accumulation and plaque-related pathology in a mouse model of amyloidosis. Molecular Neurodegeneration, 2022, 17, 13.	4.4	44
311	Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment. JAMA Network Open, 2022, 5, e228392.	2.8	44
312	The informed road map to prevention of Alzheimer Disease: A call to arms. Molecular Neurodegeneration, 2021, 16, 49.	4.4	43
313	In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS. PLoS ONE, 2012, 7, e38013.	1.1	43
314	Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. Journal of Alzheimer's Disease, 2010, 21, 833-42.	1.2	43
315	Cellular Catabolism of Lipid Poor Apolipoprotein E via Cell Surface LDL Receptor-Related Protein. Journal of Biochemistry, 2002, 132, 743-749.	0.9	42
316	Blocking the apoE/AÎ² interaction ameliorates AÎ²-related pathology in APOE Îµ2 and Îµ4 targeted replacement Alzheimer model mice. Acta Neuropathologica Communications, 2014, 2, 75.	2.4	42
317	Human Central Nervous System (CNS) ApoE Isoforms Are Increased by Age, Differentially Altered by Amyloidosis, and Relative Amounts Reversed in the CNS Compared with Plasma. Journal of Biological Chemistry, 2016, 291, 27204-27218.	1.6	42
318	Moving towards a vaccine. Nature, 2008, 454, 419-420.	13.7	41
319	AMPA-ergic regulation of amyloid-Î² levels in an Alzheimerâ€™s disease mouse model. Molecular Neurodegeneration, 2018, 13, 22.	4.4	41
320	Astrocytic Î±2-Na ⁺ /K ⁺ ATPase inhibition suppresses astrocyte reactivity and reduces neurodegeneration in a tauopathy mouse model. Science Translational Medicine, 2022, 14, eabm4107.	5.8	40
321	Acute dosing of latrepirdine (Dimebonâ„¢), a possible Alzheimer therapeutic, elevates extracellular amyloid-Î² levels in vitro and in vivo. Molecular Neurodegeneration, 2009, 4, 51.	4.4	39
322	Antibody Therapeutics Targeting AÎ² and Tau. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a024331.	2.9	39
323	Calcium-Stimulated Adenylyl Cyclases Modulate Ethanol-Induced Neurodegeneration in the Neonatal Brain. Journal of Neuroscience, 2005, 25, 2376-2385.	1.7	38
324	Effects of CD2-associated protein deficiency on amyloid-Î² in neuroblastoma cells and in an APP transgenic mouse model. Molecular Neurodegeneration, 2015, 10, 12.	4.4	37

#	Article	IF	Citations
325	Expression of neuronal-NOS in developing basal forebrain cholinergic neurons: Regulation by NGF. Neurochemical Research, 1996, 21, 861-868.	1.6	36
326	Critical Issues for Successful Immunotherapy in Alzheimers Disease: Development of Biomarkers and Methods for Early Detection and Intervention. CNS and Neurological Disorders - Drug Targets, 2009, 8, 144-159.	0.8	36
327	Sleep deprivation differentially affects dopamine receptor subtypes in mouse striatum. NeuroReport, 2011, 22, 489-493.	0.6	36
328	Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimerâ€™s disease biomarkers. Neurobiology of Aging, 2015, 36, 1771-1779.	1.5	36
329	Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model. Annals of Neurology, 2021, 89, 952-966.	2.8	36
330	Identifying amyloid pathologyâ€“related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 339-348.	1.2	35
331	Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. Neurology, 2021, 97, e1823-e1834.	1.5	35
332	Targeting tauopathy with engineered tau-degrading intrabodies. Molecular Neurodegeneration, 2019, 14, 38.	4.4	33
333	In situ AFM studies of astrocyte-secreted apolipoprotein E- and J-containing lipoproteins. Journal of Colloid and Interface Science, 2004, 278, 96-106.	5.0	32
334	The microbiome: A target for Alzheimer disease?. Cell Research, 2019, 29, 779-780.	5.7	32
335	Diffusion characteristics associated with neuronal injury and glial activation following hypoxiaâ€ischemia in the immature brain. Magnetic Resonance in Medicine, 2011, 66, 839-845.	1.9	31
336	Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice. Brain Research, 2012, 1467, 120-132.	1.1	31
337	Functional insights from biophysical study of TREM2 interactions with apoE and AÎ²_{1â€42}. Alzheimer's and Dementia, 2021, 17, 475-488.	0.4	31
338	Potential Role of apoE in Structural Plasticity in the Nervous System. Trends in Cardiovascular Medicine, 1998, 8, 250-255.	2.3	30
339	SEQUIN Multiscale Imaging of Mammalian Central Synapses Reveals Loss of Synaptic Connectivity Resulting from Diffuse Traumatic Brain Injury. Neuron, 2020, 107, 257-273.e5.	3.8	30
340	Cerebral Amyloid Angiopathy Increases Susceptibility to Infarction After Focal Cerebral Ischemia in Tg2576 Mice. Stroke, 2014, 45, 3064-3069.	1.0	27
341	Cerebrospinal Fluid Levels of Amyloid Precursor Protein Are Associated with Ventricular Size in Post-Hemorrhagic Hydrocephalus of Prematurity. PLoS ONE, 2015, 10, e0115045.	1.1	27
342	African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. Neurology: Genetics, 2021, 7, e571.	0.9	27

#	Article	IF	Citations
343	The Modulating Effect of Mechanical Changes in Lipid Bilayers Caused by ApoE-Containing Lipoproteins on AÎ² Induced Membrane Disruption. ACS Chemical Neuroscience, 2011, 2, 588-599.	1.7	26
344	Diurnal oscillation of CSF AÎ² and other AD biomarkers. Molecular Neurodegeneration, 2017, 12, 36.	4.4	26
345	Cortical Binding of Pittsburgh Compound B, an Endophenotype for Genetic Studies of Alzheimer's Disease. Biological Psychiatry, 2010, 67, 581-583.	0.7	25
346	CSF biomarkers of Alzheimer disease. Neurology, 2013, 81, 2028-2031.	1.5	25
347	Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits. Scientific Reports, 2016, 6, .	1.6	25
348	APOE Genotype Differentially Modulates Effects of Anti-AÎ², Passive Immunization in APP Transgenic Mice. Molecular Neurodegeneration, 2017, 12, 12.	4.4	25
349	Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults.. Neuropsychology, 2015, 29, 368-381.	1.0	24
350	Lumbar Cerebrospinal Fluid Biomarkers of Posthemorrhagic Hydrocephalus of Prematurity: Amyloid Precursor Protein, Soluble Amyloid Precursor Protein Î±, and L1 Cell Adhesion Molecule. Neurosurgery, 2017, 80, 82-90.	0.6	24
351	Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. Brain, 2018, 141, 3233-3248.	3.7	24
352	Measurement of apolipoprotein E and amyloid Î² clearance rates in the mouse brain using bolus stable isotope labeling. Molecular Neurodegeneration, 2012, 7, 14.	4.4	23
353	Apolipoprotein E mediation of neuro-inflammation in a murine model of multiple sclerosis. Journal of Neuroimmunology, 2014, 271, 8-17.	1.1	23
354	Nmnat1 protects neuronal function without altering phosphoâ€tau pathology in a mouse model of tauopathy. Annals of Clinical and Translational Neurology, 2016, 3, 434-442.	1.7	23
355	â€œAlzheimer's diseaseâ€•is neither â€œAlzheimer's clinical syndromeâ€•nor â€œdementiaâ€• Alzheimer's and Dementia, 2019, 15, 153-157.	0.4	23
356	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. JAMA Network Open, 2019, 2, e1917126.	2.8	23
357	Progress Update: Fluid and Imaging Biomarkers in Alzheimerâ€™s Disease. Biological Psychiatry, 2014, 75, 520-526.	0.7	22
358	Translocator protein in late stage Alzheimerâ€™s disease and Dementia with Lewy bodies brains. Annals of Clinical and Translational Neurology, 2019, 6, 1423-1434.	1.7	22
359	No effect of apolipoprotein E on neuronal cell death due to excitotoxic and apoptotic agents in vitro and neonatal hypoxic ischaemia in vivo. European Journal of Neuroscience, 2000, 12, 2235-2242.	1.2	21
360	Use of YFP to study amyloid-Î² associated neurite alterations in live brain slices. Neurobiology of Aging, 2003, 24, 1071-1077.	1.5	21

#	Article	IF	Citations
361	Senescent glia spell trouble in Alzheimerâ€™s disease. Nature Neuroscience, 2019, 22, 683-684.	7.1	21
362	Cerebrospinal fluid biomarkers of infantile congenital hydrocephalus. PLoS ONE, 2017, 12, e0172353.	1.1	21
363	Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside. Journal of Clinical Investigation, 2021, 131, .	3.9	21
364	Lack of X-Linked Inhibitor of Apoptosis Protein Leads to Increased Apoptosis and Tissue Loss Following Neonatal Brain Injury. ASN Neuro, 2009, 1, AN20090005.	1.5	20
365	Re-evaluation of the Blood-Brain Barrier in the Presence of Alzheimerâ€™s Disease Pathology. Neuron, 2015, 88, 237-239.	3.8	19
366	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. Brain Connectivity, 2021, 11, 239-249.	0.8	18
367	A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimerâ€™s disease. Brain Communications, 2022, 4, fcac045.	1.5	17
368	Sigma-2 receptor binding is decreased in female, but not male, APP/PS1 mice. Biochemical and Biophysical Research Communications, 2015, 460, 439-445.	1.0	16
369	STAT3 inhibitor mitigates cerebral amyloid angiopathy and parenchymal amyloid plaques while improving cognitive functions and brain networks. Acta Neuropathologica Communications, 2021, 9, 193.	2.4	16
370	Differential metabolism of ApoE isoforms in plasma and CSF. Experimental Neurology, 2003, 183, 4-6.	2.0	15
371	Amyloid-Î² Immunotherapies in Mice and Men. Alzheimer Disease and Associated Disorders, 2006, 20, 118-123.	0.6	15
372	A single dose of the Î³-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans. Alzheimer's Research and Therapy, 2016, 8, 11.	3.0	15
373	Multiple Î³-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimerâ€™s disease subjects. Molecular Neurodegeneration, 2012, 7, 16.	4.4	14
374	Pretreatment with Human Chorionic Gonadotropin Protects the Neonatal Brain against the Effects of Hypoxic-Ischemic Injury. Frontiers in Pediatrics, 2017, 5, 232.	0.9	14
375	Expression of Human Apolipoprotein E Downregulates Amyloid Precursor Proteinâ€“Induced Ischemic Susceptibility. Stroke, 2002, 33, 1905-1910.	1.0	12
376	Effects of growth hormoneâ€“releasing hormone on sleep and brain interstitial fluid amyloid-Î² in an APP transgenic mouse model. Brain, Behavior, and Immunity, 2015, 47, 163-171.	2.0	12
377	Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40. BMC Neurology, 2016, 16, 217.	0.8	12
378	NMNAT3 is protective against the effects of neonatal cerebral hypoxiaâ€ischemia. Annals of Clinical and Translational Neurology, 2017, 4, 722-738.	1.7	12

#	Article	IF	Citations
379	In Search of an Identity for Amyloid Plaques. Trends in Neurosciences, 2018, 41, 483-486.	4.2	12
380	AÎ² conformational change is central to Alzheimerâ€™s disease. Neurobiology of Aging, 2002, 23, 1085-1088.	1.5	11
381	Neuropsychiatric Symptoms and Alzheimerâ€™s Disease Biomarkers Predict Driving Decline: Brief Report. Journal of Alzheimer's Disease, 2017, 58, 675-680.	1.2	11
382	Depression and Alzheimerâ€™s Disease Biomarkers Predict Driving Decline. Journal of Alzheimer's Disease, 2018, 66, 1213-1221.	1.2	11
383	Dementia is not synonymous with Alzheimerâ€™s disease. Science Translational Medicine, 2019, 11, .	5.8	11
384	APOE Antibody Inhibits AÎ²â€Associated Tau Seeding and Spreading in a Mouse Model. Annals of Neurology, 2022, 91, 847-852.	2.8	11
385	An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-Îµ4 in female patients with Alzheimerâ€™s disease. Nature Aging, 2022, 2, 616-634.	5.3	11
386	Multi-Modal Home Sleep Monitoring in Older Adults. Journal of Visualized Experiments, 2019, , .	0.2	10
387	Regional Age-Related Atrophy After Screening for Preclinical Alzheimer Disease. Neurobiology of Aging, 2021, 109, 43-51.	1.5	9
388	Murine roseolovirus does not accelerate amyloid-Î² pathology and human roseoloviruses are not over-represented in Alzheimer disease brains. Molecular Neurodegeneration, 2022, 17, 10.	4.4	9
389	Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future â€œNon-Cognitiveâ€• Outcomes of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 52, 1055-1064.	1.2	8
390	Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers. , 2018, 14, 610-616.		8
391	Comparison of single-channel EEG, actigraphy, and sleep diary in cognitively normal and mildly impaired older adults. SLEEP Advances, 2020, 1, zpaa006.	0.1	8
392	Network dysfunction in cognitively normal APOE Îµ4 carriers is related to subclinical tau. Alzheimer's and Dementia, 2022, 18, 116-126.	0.4	7
393	Cognitively normal APOE Îµ4 carriers have specific elevation of CSF SNAP-25. Neurobiology of Aging, 2021, 102, 64-72.	1.5	7
394	Adverse driving behaviors are associated with sleep apnea severity and age in cognitively normal older adults at risk for Alzheimerâ€™s disease. Sleep, 2022, 45, .	0.6	7
395	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. Neurobiology of Disease, 2022, 168, 105714.	2.1	7
396	Potential Role of Endogenous and Exogenous Amyloid-Beta Binding Molecules in the Pathogenesis, Diagnosis, and Treatment of Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2003, 17, 151-153.	0.6	6

#	Article	IF	Citations
397	Using the A/T/N Framework to Examine Driving in Preclinical Alzheimerâ€™s Disease. Geriatrics (Switzerland), 2018, 3, 23.	0.6	6
398	Role of A Î² Transport and Clearance in the Pathogenesis and Treatment of Alzheimerâ€™s Disease. , 2007, , 179-198.		6
399	Dr. Jekyll and Mr. Hyde: ApoE explains opposing effects of neuronal LRP1. Journal of Clinical Investigation, 2019, 129, 969-971.	3.9	6
400	The human trisomy 21 brain: Insights from mouse models of Down syndrome. Mental Retardation and Developmental Disabilities Research Reviews, 1996, 2, 66-72.	3.5	5
401	Recent Advances from the Bench Toward the Bedside in Alzheimer's Disease. EBioMedicine, 2015, 2, 94-95.	2.7	5
402	Endothelial ether lipids link the vasculature to blood pressure, behavior, and neurodegeneration. Journal of Lipid Research, 2021, 62, 100079.	2.0	5
403	Human Neurons Derived From Induced Pluripotent Stem Cells as a New Platform for Preclinical Drug Screening and Development. JAMA Neurology, 2014, 71, 1475.	4.5	4
404	Automated selective disruption of slow wave sleep. Journal of Neuroscience Methods, 2017, 281, 33-39.	1.3	4
405	Targeting pre-synaptic tau accumulation: a new strategy to counteract tau-mediated synaptic loss and memory deficits. Neuron, 2021, 109, 741-743.	3.8	4
406	Effects of COVID-19 on preclinical and clinical research in neurology: Examples from research on neurodegeneration and Alzheimerâ€™s disease. Neuron, 2021, 109, 3199-3202.	3.8	4
407	Reply to: Fractional synthesis and clearance rates for amyloid Î². Nature Medicine, 2011, 17, 1179-1180.	15.2	3
408	<scp>CSF sTREM</scp> 2: marking the tipping point between preclinical <scp>AD</scp> and dementia?. EMBO Molecular Medicine, 2016, 8, 437-438.	3.3	3
409	Small Molecule Phenotypic Screen Identifies Novel Regulators of LDLR Expression. ACS Chemical Biology, 2020, 15, 3262-3274.	1.6	3
410	Differences in the AÎ²40/AÎ²42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Annals of Neurology, 2000, 48, 201-210.	2.8	3
411	Amyloid-Î² Binding Molecule. Alzheimer Disease and Associated Disorders, 2003, 17, S66-S68.	0.6	2
412	Cerebrospinal Fluid Î²-Amyloid 42, Tau, and P-tau. Archives of Neurology, 2009, 66, 1552-3.	4.9	2
413	P2-085: Task-switching errors show sensitivity to preclinical Alzheimer's disease biomarkers. , 2015, 11, P516-P516.		2
414	Amyloid-Î² â€˜seedsâ€™ in old vials of growth hormone. Nature, 2018, 564, 354-355.	13.7	2

#	Article	IF	Citations
415	Immigration in science. Journal of Experimental Medicine, 2020, 217, .	4.2	2
416	Reply to â€œInhibition of post-ischemic brain injury by clusterin overexpressionâ€• Nature Medicine, 2001, 7, 978-979.	15.2	1
417	Stealth Attack: Plaque-Specific Antibody Allows for Efficient AÎ² Removal without Side Effects. Neuron, 2012, 76, 859-861.	3.8	1
418	P2-130: Amyloid imaging and cerebrospinal fluid biomarkers predict driving performance in preclinical Alzheimer's disease. , 2015, 11, P533-P534.		1
419	F2-02-02: Effects of disrupted sleep on abeta and tau pathology and effects of abeta and tau pathology on sleep: A vicious cycle?. , 2015, 11, P165-P166.		1
420	Is there a link between the sleepâ€“wake cycle and Alzheimer's pathology?. Future Neurology, 2015, 10, 183-186.	0.9	1
421	O2â€03â€02: are White Matter Hyperintensities a Core Feature of Alzheimerâ€™s Disease or Just a Reflection of Amyloid Angiopathy? Evidence From the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's and Dementia, 2016, 12, P226.	0.4	1
422	O5-03-01: Apolipoprotein E Genotype Differentially Modulates Effects of ANTI-AB Immunotherapy. , 2016, 12, P381-P382.		1
423	P1-006: Emerging CSF Biomarkers of Neuroinflammation, Neuronal Injury And Synaptic Integrity in the Adni Cohort. , 2016, 12, P399-P399.		1
424	[P3â€“591]: DRIVING CESSATION OVER A 22â€YEAR PERIOD: DEMENTIA SEVERITY AND CSF BIOMARKERS. Alzheimer's and Dementia, 2017, 13, P1207.	0.4	1
425	Dual therapy for AÎ² amyloidosis in AD: A successful one-two combo. Journal of Experimental Medicine, 2018, 215, 1267-1268.	4.2	1
426	APOE Îµ4 Association With Cognition and Alzheimer Disease Biomarkers in Down Syndromeâ€”Implications for Clinical Trials and Treatments for All. JAMA Neurology, 2021, 78, 913.	4.5	1
427	ANTI-AMYLOID-Î² IMMUNOTHERAPY AS A TREATMENT FOR ALZHEIMER'S DISEASE. , 2008, , 295-318.		1
428	APP-Based Transgenic Models: The PDAPP Model. Neuromethods, 2011, , 371-385.	0.2	1
429	Amyloid-beta binding molecule: potential role in the pathogenesis and treatment of Alzheimer disease. Alzheimer Disease and Associated Disorders, 2003, 17 Suppl 2, S66-8.	0.6	1
430	In Memoriam of John T. Trojanowski, MD, PhD 1946-2022. Molecular Neurodegeneration, 2022, 17, 24.	4.4	1
431	Amyloid-ss Dynamics Correlate with Neurological Status in the Injured Human Brain. , 2009, , .		0
432	A surrogate marker for AÎ²42 production in the CNS. EMBO Molecular Medicine, 2009, 1, 195-197.	3.3	0

#	Article	IF	Citations
433	IC-PL-01: Diagnostic markers: Detection of preclinical pathology, prognostic capabilities, and dynamic metabolism of Abeta and tau. , 2010, 6, S1-S1.		0
434	O1-05-01: APOE4 plays a role in Abeta-mediated synapse loss in Alzheimer's disease. , 2011, 7, S103-S104.		0
435	O2-01-01: Plasma and Cerebrospinal Fluid Markers in the DIAN Study of Autosomal-Dominant Alzheimer's Disease. , 2011, 7, S287-S287.		0
436	O3-14-03: Novel fluid biomarkers for brain amyloid and dementia risk in presymptomatic Alzheimer disease. , 2015, 11, P255-P255.		0
437	O1-01-01: Comparison of nia-aa preclinical Alzheimer's disease staging with CSF and neuroimaging biomarkers. , 2015, 11, P122-P123.		0
438	IC-P-020: Comparison of nia-aa preclinical Alzheimer's disease staging with CSF and neuroimaging biomarkers. , 2015, 11, P24-P25.		0
439	F5-03-03: Academic spin-out companies. , 2015, 11, P306-P306.		0
440	P1-221: Dynamic Relationships Between â€œBig Fiveâ€•Personality Traits, Alzheimerâ€™s Disease Biomarkers, and Cognition in Autosomal Dominant Alzheimerâ€™s Disease. , 2016, 12, P491-P492.		0
441	PLâ€01â€01: Preclinical to Clinical Translation for TAU Therapeutics. Alzheimer's and Dementia, 2016, 12, P169.	0.4	0
442	P4â€150: Preclinical Alzheimerâ€™s Disease Predicts Longitudinal Onset of Driving Difficulties Among Cognitively Normal Persons. Alzheimer's and Dementia, 2016, 12, P1071.	0.4	0
443	P4-127: Exploring the Utility of CSF Neurogranin Levels in An Alzheimerâ€™s Disease Clinical Trial. , 2016, 12, P1062-P1062.		0
444	F5â€02â€03: BDNF VAL66MET Moderates Cognitive Impairment, Neuronal Dysfunction and TAU in Preclinical Autosomal Dominant Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P369.	0.4	0
445	O5-02-01: Longitudinal Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease: The Dominantly Inherited Alzheimer Network. , 2016, 12, P378-P379.		0
446	O2â€10â€05: Cerebrospinal Fluid Levels of Amyloid Beta and Tau as Endophenotypes Reveal Novel Variants Potentially Informative for Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P252.	0.4	0
447	ICâ€Pâ€179: TAU Imaging Relationships With Amyloid B Imaging, CSF TAU/AB₄₂, and Cognition in Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P130.	0.4	0
448	Active and Passive Immunotherapy Against Tau: Effects and Potential Mechanisms. Methods in Pharmacology and Toxicology, 2016, , 121-138.	0.1	0
449	Reply. Annals of Neurology, 2017, 81, 322-323.	2.8	0
450	[P2â€“141]: TRISOMY 21 CAUSES A DEFICIT IN LYSOSOMAL CATHEPSINS AND ALTERS APP/AÎ² PROCESSING, INDEPENDENTLY OF AN EXTRA COPY OF APP. Alzheimer's and Dementia, 2017, 13, P661.	0.4	0

#	Article	IF	Citations
451	[F4â€“04â€“02]: EFFECTS OF SYNAPTIC ACTIVITY ON AÎ² AND TAU FROM PRECLINICAL IN VIVO STUDIES: SIMILARITIES, DIFFERENCES, AND IMPLICATIONS. Alzheimer's and Dementia, 2017, 13, P1215.	0.4	0
452	[P4â€“185]: NEUROPSYCHIATRIC SYMPTOMS AND ALZHEIMER DISEASE BIOMARKERS PREDICT DRIVING DECLINE. Alzheimer's and Dementia, 2017, 13, P1335.	0.4	0
453	[ICâ€Pâ€054]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P44.	0.4	0
454	[ICâ€Pâ€064]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2017, 13, P53.	0.4	0
455	[P1â€“402]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2017, 13, P427.	0.4	0
456	[O1â€“02â€“03]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P186.	0.4	0
457	[O1â€“11â€“03]: CEREBROSPINAL FLUID ENDOPHENOTYPES PROVIDE INSIGHT INTO BIOLOGY UNDERLYING ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P218.	0.4	0
458	[O2â€“01â€“05]: IMPACT OF COGNITIVE RESERVE AND PRECLINICAL AD ON LONGITUDINAL DRIVING PERFORMANCE. Alzheimer's and Dementia, 2017, 13, P550.	0.4	0
459	[P4â€“463]: PREDICTION OF INCIDENT DEMENTIA: LONGITUDINAL BIOMARKER AND CLINICAL CHANGES BEFORE AND AFTER. Alzheimer's and Dementia, 2017, 13, P1508.	0.4	0
460	[DTâ€01â€“03]: CONCENTRATIONS AND STABLE ISOTOPE LABEL KINETICS OF HUMAN PLASMA AMYLOID BETA. Alzheimer's and Dementia, 2017, 13, P1475.	0.4	0
461	Lentiviral Vector Delivery of Orexin Gene to Study Potential Role of Orexin and Sleep Modulation in the Pathogenesis of Alzheimerâ€™s Disease. , 2018, , 163-175.		0
462	Reply to â€œobstructive sleep apnea treatment and amyloidâ€Î² in cerebrospinal fluidâ€• Annals of Neurology, 2019, 85, 460-461.	2.8	0
463	Immigration in science. Journal of Experimental Medicine, 2020, 217, .	4.2	0
464	25-Hydroxycholesterol modulates tau-mediated neurodegeneration and microglial chemotaxis and phagocytosis.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e056404.	0.4	0
465	0326 Influence of Sleep and Cardiovascular Health on Cognitive Outcomes in Older Adults. Sleep, 2022, 45, A147-A147.	0.6	0